Clinical Guidance for Disease-Modifying Immunotherapy in Children and Adolescents With New-Onset (Stage 3) Type 1 Diabetes
Recommendations
As issued by the authors
Teplizumab-specific recommendations are identified, with broader principles framed for adaptation across health systems.
Original publication
Clinical Guidance for Disease-Modifying Immunotherapy in Children and Adolescents With New-Onset (Stage 3) Type 1 Diabetes. Diabetes Care. Published 11 November 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →